Skip to main content

Can we do Pulmonary Testing at Home?

Dr. Eric Dein & Dr. Zixing Liu | Abstract 1194 | ACR 2026

Transcription

Hello, this is Eric Dyne here at ACR Convergence with RheumNow. I'm here with Dr. Lou from Johns Hopkins. Tell me about your study about pulmonary function testing at home.

All right. So our study is about assessing the added value of home spirometry on top of the hospital PFTs that we're doing every 4 to 12 months. And because there is this gap in between that we're potentially missing windows of opportunity to intervene, we wanted to see if at-home testing can fill that gap.

So in our study we have three sub-questions. The first one is whether patients complete these studies, complete these readings. And then the second question is whether the home spirometry is correlated and in high agreement with the hospital PFT. And then the last question is whether we can do longitudinal trajectory modeling that's better with these denser amounts of data for home spirometries compared to the sparse data for hospital PFT.

And these are just the little spirometers that you can do at home. Yes. So these are handheld devices that they take home and then they will perform the testing, and there's an inbuilt quality control system that they have to pass, and then that will get uploaded to an app or a platform and then we can collect those data.

So tell me what you found. Yeah. So we found that in our study we have 28 patients who stayed within the study. There were originally 36 enrolled patients and then 21 of them completed at least 6 months of data. So patients do complete these home spirometry readings, and that's very encouraging.

And then the second thing that we found is that they're in high agreement, very correlated, with a coefficient of 0.99 with the hospital PFT that's matched within plus or minus 3 days for each of the patients. So they're very reliable as compared to our hospital pulmonary function test.

And then finally, we found that it can support much better and more updated estimates to understand where patients are currently and also if they're declining at a faster or slower rate.

So you can check it a little bit more serially when it's at home. Yes. And it gave us a much more granular image and it gives us more confidence if the patient is being stable or if they're improving or declining.

And this was a study specifically for scleroderma patients with established ILD. Yes. But it could presumably be used for any interstitial lung disease. It can be extended if we have a large cohort.

Thank you very much for telling us about your trial. For more coverage of ACR Convergence, tune in to RheumNow. Thank you so much. Thank you for having me.

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×